Atossa Therapeutics Inc (NASDAQ:ATOS) announced that on March 15, 2024, it received written notice from the Nasdaq that it has regained compliance with the exchange’s minimum closing bid listing requirement.
To regain compliance, the clinical-stage biopharmaceutical company was required to maintain a minimum closing bid of $1 for at least 10 consecutive trading days, which was met on March 14, 2024.